title: Author's reply to comments to: Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD.
authors.affiliation: Department of Ophthalmology, University of Basel, Basel - Switzerland.|Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Maria
authors.initials: M
authors.lastname: Waizel
authors.affiliation: Department of Ophthalmology, University of Basel, Basel - Switzerland.|Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Sara
authors.initials: S
authors.lastname: Kazerounian
authors.affiliation: Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Annekatrin
authors.initials: A
authors.lastname: Rickmann
authors.affiliation: Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar - Germany.
authors.forename: Katharina
authors.initials: K
authors.lastname: Wolf
authors.affiliation: Centre for Ophthalmology, University Eye Clinic Tübingen, Tübingen - Germany.
authors.forename: Björn R
authors.initials: BR
authors.lastname: Blanke
authors.affiliation: Department of Ophthalmology, University of Basel, Basel - Switzerland.
authors.forename: Margarita G
authors.initials: MG
authors.lastname: Todorova
mesh_terms: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab